Project Banksia involves the design, construction, validation and registration of a new state-of-the-art biopharmaceutical facility, which will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs. This will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere. The facility will also manufacture CSL Seqirus’ proprietary adjuvant MF59R and will produce unique products important to Australia’s public health needs – including antivenom for Australian snakes, spiders and marine creatures, and the world’s only human vaccine for Q-Fever.
The project will be a greenfield construction with site utilities and amenity to support the manufacturing operation, including black and clean utilities, warehousing, quality control laboratories, administration, cafeteria, car parking, etc. The facility is targeted to be operational by mid-2026.
The basic design has been completed, with the detailed design practically complete. Civil, Structural, Building Mechanical and Building Electrical contracts have been awarded for the main facility
The FCC facility concrete structure is close to practical completion and the internal fit out has commenced.
Site infrastructure is well advanced and expected to be complete in October 2022.
Remaining work packages are closing 31 Dec 2022.